Clinical Trial Update: 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating the 23-valent pneumococcal polysaccharide vaccine in patients with juvenile idiopathic arthritis receiving anti-TNF therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Juvenile Idiopathic Arthritis

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: University of Sao Paulo | Conditions: Juvenile Idiopathic Arthritis | Phase 4 | Status: COMPLETED